

# Rita Zamarchi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/686644/publications.pdf>

Version: 2024-02-01

85  
papers

3,051  
citations

236925

25  
h-index

168389

53  
g-index

87  
all docs

87  
docs citations

87  
times ranked

4695  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical significance of circulating tumor cells and cell-free DNA in pediatric rhabdomyosarcoma. <i>Molecular Oncology</i> , 2022, 16, 2071-2085.	4.6	7
2	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	3.7	5
3	Prognostic value of circulating endothelial cells in glioblastoma patients: a pilot study. <i>Future Science OA</i> , 2022, 8, .	1.9	2
4	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	6.3	22
5	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. <i>Translational Lung Cancer Research</i> , 2021, 10, 80-92.	2.8	17
6	Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor. <i>Frontiers in Pediatrics</i> , 2021, 9, 652583.	1.9	3
7	Cell-Secreted Vesicles: Novel Opportunities in Cancer Diagnosis, Monitoring and Treatment. <i>Diagnostics</i> , 2021, 11, 1118.	2.6	5
8	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021, 26, 740-750.	3.7	19
9	Pediatric sarcomas display a variable EpCAM expression in a histology-dependent manner. <i>Translational Oncology</i> , 2020, 13, 100846.	3.7	8
10	Liquid Biopsy in Pediatric Renal Cancer: Stage I and Stage IV Cases Compared. <i>Diagnostics</i> , 2020, 10, 810.	2.6	1
11	Possible role of circulating tumor cells in early detection of lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 3821-3835.	1.4	8
12	Mathematical models for HIV treatment : A schematic review. <i>Journal of Interdisciplinary Mathematics</i> , 2020, 23, 707-725.	0.7	1
13	Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 61-68.	2.5	15
14	Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q. <i>Journal of Thoracic Disease</i> , 2020, 12, 2771-2780.	1.4	13
15	Dynamic changes of Receptor activator of nuclear factor- $\kappa$ B expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer. <i>Scientific Reports</i> , 2020, 10, 1288.	3.3	25
16	Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer. <i>Cancers</i> , 2020, 12, 1005.	3.7	5
17	Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2020, 11, 4115-4122.	1.8	10
18	Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?. <i>Frontiers in Genetics</i> , 2019, 10, 958.	2.3	53

#	ARTICLE	IF	CITATIONS
19	Detection and Prognostic Relevance of Circulating and Disseminated Tumour Cell in Dogs with Metastatic Mammary Carcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 163.	3.7	13
20	Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells. <i>Melanoma Research</i> , 2019, 29, 89-94.	1.2	4
21	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	4.4	200
22	Single tube liquid biopsy for advanced non-small cell lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 3127-3137.	5.1	45
23	EpCAM <sup>high</sup> and EpCAM <sup>low</sup> circulating tumor cells in metastatic prostate and breast cancer patients. <i>Oncotarget</i> , 2018, 9, 35705-35716.	1.8	70
24	What information could the main actors of liquid biopsy provide? A representative case of non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018, 10, E570-E576.	1.4	9
25	The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. <i>Diagnostics</i> , 2018, 8, 59.	2.6	57
26	Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap). <i>International Journal of Cancer</i> , 2018, 143, 2584-2591.	5.1	68
27	Possible applications of circulating tumor cells in patients with non small cell lung cancer. <i>Lung Cancer</i> , 2017, 107, 59-64.	2.0	17
28	Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017, 9, S1346-S1358.	1.4	18
29	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. <i>Journal of Thoracic Disease</i> , 2017, 9, S1391-S1396.	1.4	8
30	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4568-4568.	1.6	4
31	Circulating Tumor Cells (CTCs) and Metastatic Prostate Cancer (mPCa). , 2017, , 47-59.		0
32	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK <sup>+</sup> Positive Non-small Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2016, 17, e173-e177.	2.6	22
33	Grp94 in complexes with IgG is a soluble diagnostic marker of gastrointestinal tumors and displays immune-stimulating activity on peripheral blood immune cells. <i>Oncotarget</i> , 2016, 7, 72923-72940.	1.8	11
34	HIV vs. the Immune System: A Differential Game. <i>Mathematics</i> , 2015, 3, 1139-1170.	2.2	5
35	First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response. <i>Familial Cancer</i> , 2015, 14, 309-316.	1.9	21
36	Notes for developing a molecular test for the full characterization of circulating tumor cells. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2015, 27, 471-8.	2.2	1

#	ARTICLE	IF	CITATIONS
37	Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2014, 15, 406-414.	10.7	703
38	Circulating tumor cells: utopia or reality?. <i>Future Oncology</i> , 2013, 9, 1337-1352.	2.4	20
39	Zoledronic Acid Induces a Significant Decrease of Circulating Endothelial Cells and Circulating Endothelial Precursor Cells in the Early Prostate Cancer Neoadjuvant Setting. <i>Oncology</i> , 2013, 85, 342-347.	1.9	11
40	Customizing CellSearch platform. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2013, 83A, 595-598.	1.5	4
41	Retaining the long-survive capacity of Circulating Tumor Cells (CTCs) followed by xeno-transplantation: not only from metastatic cancer of the breast but also of prostate cancer patients. <i>Oncoscience</i> , 2013, 1, 49-56.	2.2	52
42	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer. <i>British Journal of Cancer</i> , 2012, 107, 1286-1294.	6.4	55
43	Inhibition of immunoglobulin secretion from peripheral blood mononuclear cells by glucose-regulated protein94 (Grp94) in allergic subjects. <i>Molecular and Cellular Biochemistry</i> , 2012, 365, 47-52.	3.1	0
44	Effects of glucose-regulated protein94 (Grp94) on Ig secretion from human blood mononuclear cells. <i>Cell Stress and Chaperones</i> , 2011, 16, 329-338.	2.9	6
45	Virus-Specific Cytotoxic CD4+ T Cells for the Treatment of EBV-Related Tumors. <i>Journal of Immunology</i> , 2010, 184, 5895-5902.	0.8	43
46	M30 Neoepitope Expression in Epithelial Cancer: Quantification of Apoptosis in Circulating Tumor Cells by CellSearch Analysis. <i>Clinical Cancer Research</i> , 2010, 16, 5233-5243.	7.0	124
47	Circulating and Disseminated Tumor Cells in the Clinical Management of Breast Cancer Patients: Unanswered Questions. <i>Oncology</i> , 2009, 76, 375-386.	1.9	27
48	Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN- $\gamma$ or IL-4. <i>European Journal of Immunology</i> , 2009, 39, 56-66.	2.9	24
49	DNA copy number alterations correlate with survival of esophageal adenocarcinoma patients. <i>Modern Pathology</i> , 2009, 22, 58-65.	5.5	29
50	Hypoxia Inducible Factor-1 $\alpha$ Inactivation Unveils a Link between Tumor Cell Metabolism and Hypoxia-Induced Cell Death. <i>American Journal of Pathology</i> , 2008, 173, 1186-1201.	3.8	39
51	The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN- $\gamma$ Antitumor Effects. <i>Cancer Research</i> , 2008, 68, 5658-5668.	0.9	121
52	Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis. <i>Cancer Research</i> , 2007, 67, 8605-8614.	0.9	41
53	A lymphotactin-producing monoclonal T-cell lymphoproliferative disorder with extreme lymphocytopenia and progressive leukoencephalopathy. <i>Leukemia and Lymphoma</i> , 2006, 47, 1421-1423.	1.3	5
54	Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 4216-4221.	7.1	113

#	ARTICLE	IF	CITATIONS
55	Chemokine receptor expression in EBV-associated lymphoproliferation in hu/SCID mice: implications for CXCL12/CXCR4 axis in lymphoma generation. <i>Blood</i> , 2005, 105, 931-939.	1.4	38
56	B cell activation in peripheral blood and lymph nodes during HIV infection. <i>Aids</i> , 2002, 16, 1217-1226.	2.2	13
57	Expression from cell type-specific enhancer-modified retroviral vectors after transduction: influence of marker gene stability. <i>Gene</i> , 2002, 283, 199-208.	2.2	11
58	Alternatively spliced forms of Ig $\lambda$ and Ig $\mu$ prevent B cell receptor expression on the cell surface. <i>European Journal of Immunology</i> , 2002, 32, 1530.	2.9	19
59	Infection of simian B lymphoblastoid cells with simian immunodeficiency virus is associated with upregulation of CD23 and CD40 cell surface markers. <i>Journal of Medical Virology</i> , 2002, 68, 129-140.	5.0	6
60	Expression and functional activity of CXCR-4 and CCR-5 chemokine receptors in human thymocytes. <i>Clinical and Experimental Immunology</i> , 2002, 127, 321-330.	2.6	32
61	Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. <i>Blood</i> , 2001, 98, 3607-3617.	1.4	28
62	Modulation of Moloney Leukemia Virus Long Terminal Repeat Transcriptional Activity by the Murine CD4 Silencer in Retroviral Vectors. <i>Virology</i> , 2000, 276, 83-92.	2.4	10
63	Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child. <i>Aids</i> , 2000, 14, 1284.	2.2	9
64	Frequency of a Mutated CCR-5 Allele (Delta32) among Italian Healthy Donors and Individuals at Risk of Parenteral HIV Infection. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 337-344.	1.1	20
65	CD4 and CD8 T lymphocyte inheritance. Evidence for major autosomal recessive genes. <i>Human Genetics</i> , 1999, 105, 337-342.	3.8	10
66	DNA Immunization of Mice against SIVmac239 Gag and Env Using Rev-Independent Expression Plasmids. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 83-90.	1.1	22
67	Effect of rIL-2 treatment on anti-tetanus toxoid response in the elderly. <i>Mechanisms of Ageing and Development</i> , 1997, 93, 205-214.	4.6	4
68	TCR Expression and Clonality Analysis in Peripheral Blood and Lymph Nodes of HIV-Infected Patients. <i>Human Immunology</i> , 1997, 57, 93-103.	2.4	13
69	Reply to cole. <i>Trends in Immunology</i> , 1997, 18, 506-507.	7.5	0
70	Reply to Bostik et al.. <i>Trends in Immunology</i> , 1997, 18, 556.	7.5	0
71	Vaccination of Cynomolgus Monkeys with Whole Inactivated or Live-Attenuated Simian Immunodeficiency Virus. <i>Antibiotics and Chemotherapy</i> , 1996, 48, 131-138.	0.5	0
72	Genetic variability of the human CD4 V2 domain. <i>Immunogenetics</i> , 1996, 44, 70-72.	2.4	7

#	ARTICLE	IF	CITATIONS
73	CD4:CD8 ratio and HIV infection: the "tap-and-drain" hypothesis. Trends in Immunology, 1996, 17, 414-417.	7.5	31
74	Genetic variability of the human CD4 V2 domain. Immunogenetics, 1996, 44, 70-72.	2.4	0
75	Genetic control of the CD4/CD8 T-cell ratio in humans. Nature Medicine, 1995, 1, 1279-1283.	30.7	398
76	A CD3+CD8+ T Cell Population Lacking CD5 Antigen Expression Is Expanded in Peripheral Blood of Human Immunodeficiency Virus-Infected Patients. Clinical Immunology and Immunopathology, 1995, 77, 253-261.	2.0	28
77	B And T Cell Function Parameters During Zidovudine Treatment Of Human Immunodeficiency Virus-Infected Patients. Journal of Infectious Diseases, 1994, 170, 1148-1156.	4.0	7
78	B cell activation and human immunodeficiency virus infection. V. Phenotypic and functional alterations in CD5+ and CD5? B cell subsets. Journal of Clinical Immunology, 1993, 13, 381-388.	3.8	25
79	Quantitative and qualitative analysis of anti-tetanus toxoid antibody response in the elderly. Humoral immune response enhancement by thymostimulin. Vaccine, 1993, 11, 1336-1340.	3.8	25
80	Standardization of in vitro synthesis and detection of HIV-1-specific antibodies. Journal of Immunological Methods, 1993, 157, 105-115.	1.4	13
81	In Vitro Spontaneous Production of Anti-SIV Antibodies Is a Reliable Tool in the Follow-Up of Protection of SIV-Vaccinated Monkeys. AIDS Research and Human Retroviruses, 1993, 9, 1139-1144.	1.1	6
82	B-cell activation during HIV-1 infection. III. Down-regulating effect of mitogens. Aids, 1991, 5, 821-828.	2.2	22
83	IgG Oligoclonal Bands in Sera of HIV-1 Infected Patients Are Mainly Directed Against HIV-1 Determinants. AIDS Research and Human Retroviruses, 1990, 6, 581-586.	1.1	37
84	Immune dysfunction in the elderly: Effect of thymic hormone administration on several in vivo and in vitro immune function parameters. Aging Clinical and Experimental Research, 1990, 2, 347-355.	2.9	3
85	In vitro malignant progression of cells derived from Abelson murine leukaemia virus-induced thymic lymphomas. British Journal of Cancer, 1988, 58, 152-157.	6.4	3